GlassScriptPhysician profile
Peter H Law
NPI 1265658629
$6,888.95
in general payments reported to CMS, 2019-2025
30 companies · $4,668 in 2025
The $4,668 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $223 · 2021: $371 · 2022: $378 · 2023: $302 · 2024: $612 · 2025: $4,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,649 · Travel and Lodging: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,648.99 |
| Travel and Lodging | $1,433.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,950.15 | 2025 | |
| Glaxosmithkline, LLC. | $1,031.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $253.07 | 2022-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $191.63 | 2022-2025 | |
| Insmed, INC. | $189.57 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $163.86 | 2024-2025 | Dupixent |
| United Therapeutics Corporation | $120.09 | 2019-2023 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.96 | 2022-2025 | Jascayd, Ofev |
| Genentech USA, INC. | $106.91 | 2023-2025 | Xolair |
| Grifols USA, LLC | $106.47 | 2019-2025 | Prolastin-C Liquid |
| Medtronic Vascular, INC. | $92.22 | 2019 | |
| Pfizer INC. | $63.58 | 2021-2022 | |
| Mylan Specialty L.P. | $59.28 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $59.01 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $53.52 | 2021-2025 | Zerbaxa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $41.89 | 2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $40.88 | 2021-2022 | |
| Verona Pharma, INC. | $35.33 | 2025 | Ohtuvayre |
| Abbvie INC. | $31.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.47 | 2022-2023 | |
| Baxter Healthcare | $25.16 | 2024 | Hillrom - Monarch Airway Clearance System |
| Caris Mpi, INC. | $18.85 | 2025 | Mi Cancer Seek |
| Ambu INC. | $18.79 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $16.46 | 2021 | |
| La Jolla Pharmaceutical Company | $16.14 | 2022 | |
| Lilly USA, LLC | $14.71 | 2025 | Zepbound |
| Amgen INC. | $13.92 | 2024 | Tezspire |
| Allergan, INC. | $13.28 | 2020 | |
| Gilead Sciences, INC. | $11.97 | 2021 | |
| Vapotherm INC | $9.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.